Lantheus has been instrumental in pioneering the field of medical imaging. For more than 60 years, we have helped physicians enhance patient care with our broad product portfolio of imaging agents and products that illuminate the heart, brain, lungs and other organs.
Dr. Edward Shapiro, a proponent for the Atoms for Peace initiative and an innovator in using radioactive isotopes in medicine and science, co-founded New England Nuclear (NEN) with Seymour Rothschild in 1956. The company grew to become a leader in the field of diagnostic imaging. In 1981, the company was purchased by E.I. du Pont de Nemours and Company (DuPont). Bristol-Myers Squibb Company (BMS) subsequently acquired the diagnostic medical imaging business as part of its acquisition of DuPont Pharmaceuticals in 2001.
In 2008, BMS Medical Imaging was acquired by Avista Capital Partners, a private equity firm based in New York City, and was formally re-launched as Lantheus Medical Imaging. In June 2015, parent company Lantheus Holdings [LNTH] became a NASDAQ listed company. In 2020, Lantheus acquired Progenics Pharmaceuticals. The Progenics acquisition added a pipeline of radiotherapeutics, targeted PET imaging agents and small molecule therapeutics in the oncology space.